Oprozomib

DB11991InvestigationalSmall molecule

Oprozomib has been used in trials studying the treatment of Solid Tumors, Multiple Myeloma, Waldenstrom Macroglobulinemia, Advanced Hepatocellular Carcinoma, and Advanced Non-Central Nervous System (CNS) Malignancies.

Mechanism: Pharmacologically active on Proteasome subunit beta type-5
Curator reviewed
Formula / weight: C₂₅H₃₂N₄O₇S · 532.61 g/mol (avg)
Code names: ONX-0912

Resolves to

Compound

UNIIMZ37792Y8JCAS935888-69-0ChEMBLCHEMBL2103884PubChem25067547

Structure

InChIKeySWZXEVABPLUDIO-WSZYKNRRSA-NSMILESCOC[C@H](NC(=O)[C@H](COC)NC(=O)C1=CN=C(C)S1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)[C@@]1(C)CO1

Targets

P28074PSMB5

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Oprozomib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account